(0.33%) 5 116.74 points
(0.31%) 38 359 points
(0.37%) 15 986 points
(-0.88%) $83.11
(5.93%) $2.04
(0.40%) $2 356.70
(0.42%) $27.65
(3.89%) $957.95
(-0.22%) $0.933
(-0.37%) $10.98
(-0.54%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases...
Stats | |
---|---|
本日の出来高 | 8 976.00 |
平均出来高 | 330 263 |
時価総額 | 7.67M |
EPS | $-0.175 ( 2023-06-29 ) |
次の収益日 | ( $0 ) 2024-05-24 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0100 |
ATR14 | $0.00100 (7.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-17 | Ji Henry | Buy | 19 500 | Common Stock |
2023-03-17 | Ji Henry | Sell | 195 | Put Option (obligation to buy) |
2021-12-31 | Janda Kim | Buy | 0 | |
2022-12-21 | Ji Henry | Buy | 300 | Common Stock |
2022-12-02 | Ji Henry | Buy | 200 | Common Stock |
INSIDER POWER |
---|
99.97 |
Last 96 transactions |
Buy: 40 331 586 | Sell: 980 682 |
Sorrento Therapeutics Inc 相関
10 最も負の相関 | |
---|---|
ESCA | -0.906 |
BREZ | -0.903 |
BRLI | -0.886 |
OPRA | -0.882 |
ITAQU | -0.882 |
AUPH | -0.882 |
GRIL | -0.877 |
PBBK | -0.874 |
ESPO | -0.873 |
CNGL | -0.873 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Sorrento Therapeutics Inc 財務諸表
Annual | 2022 |
収益: | $62.84M |
総利益: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2022 |
収益: | $62.84M |
総利益: | $29.39M (46.77 %) |
EPS: | $-1.330 |
FY | 2021 |
収益: | $52.90M |
総利益: | $39.87M (75.37 %) |
EPS: | $-1.450 |
FY | 2020 |
収益: | $39.99M |
総利益: | $30.05M (75.14 %) |
EPS: | $-1.300 |
Financial Reports:
No articles found.
Sorrento Therapeutics Inc
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。